The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PYXS | +2.72% | N/A | N/A | -89% |
| S&P | +13.95% | +78.35% | +12.25% | +58% |
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Cambridge, MA.
No news articles found for Pyxis Oncology.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$527.00K | 27.9% |
| Gross Margin | 81.03% | 0.0% |
| Market Cap | $137.68M | -36.9% |
| Market Cap / Employee | $3.13M | 0.0% |
| Employees | 44 | 0.0% |
| Net Income | -$22,003.00K | -3.8% |
| EBITDA | -$22,934.00K | 0.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.39M | -23.2% |
| Accounts Receivable | $3.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.44M | -8.9% |
| Short Term Debt | $1.63M | 17.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -64.53% | -34.5% |
| Return On Invested Capital | -80.16% | -8.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13,286.00K | 9.3% |
| Operating Free Cash Flow | -$13,277.00K | 9.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.60 | 0.49 | 0.66 | 1.57 | 23.36% |
| Price to Sales | 13.80 | 5.76 | 24.15 | 49.25 | 297.10% |
| Price to Tangible Book Value | 0.71 | 0.50 | 0.67 | 1.62 | 9.27% |
| Enterprise Value to EBITDA | 0.82 | 1.22 | 0.15 | -3.50 | -17.04% |
| Return on Equity | -62.8% | -66.3% | -74.8% | -87.3% | 121.89% |
| Total Debt | $20.20M | $19.84M | $19.46M | $19.07M | -7.14% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
